Table 4.
Survival outcomes of patients with castration-resistant prostate cancer, stratified by clinical trial participation
| Overall (n = 299) |
Clinical trial | |||
|---|---|---|---|---|
| Participants (n = 65) |
Non-participants (n = 234) |
p | ||
| No. cancer-specific deaths | 187 (62.5%) | 44 (67.7%) | 143 (61.1%) | 0.364 |
| 2-year cancer-specific survival | 46.8% | 61.3% | 42.4% | 0.003 |
| CRPC to death (months) | 13.0 (6.0–24.3) | 23.5 (13.3–30.5) | 11.0 (5.0–19.3) | < 0.001 |
| Total follow-up (months) | 16.0 (7.2–26.0) | 26.0 (16.0–39.8) | 13.5 (6.0–24.0) | < 0.001 |
Data are presented as number (%) or median (interquartile range)
Abbreviations: CRPC castration-resistant prostate cancer